Dublin, May 22, 2025 (GLOBE NEWSWIRE) -- The "Semaglutide Market Size, Share & Trends Analysis Report by Product (Ozempic, Wegovy, Rybelsus), Application (Type 2 Diabetes Mellitus, Obesity), Route ...

With VKTX surging on clinical results and NVO investing to cement market share, investors face a high-stake GLP-1 showdown.

"We are introducing Wegovy (injectable Semaglutide 2.4 mg) this year, which offers full therapeutic strengths of semaglutide ...

Amble Health's website states it is a platform connecting patients to licensed healthcare professionals online, who can ...

ASHLAND A weight loss clinic with multiple locations in Kentucky, including Ashland, is facing accusations of providing ...

Northern Ireland will open its first specialist weight management service next year, which will provide access to obesity drugs such as glucagon-like peptide-1 receptor agonists, health minister Mike ...

Tirzepatide, the newest weight loss drug in India, is transforming the wellness market with its hormone-mimicking effects.

Rybelsus (semaglutide) is the first GLP-1 agonist drug that can be dosed orally, and is Novo Nordisk's third drug in the class after daily injectable Victoza (liraglutide) and weekly shot Ozempic ...

while the University of Colorado has an ongoing 135-patient trial of oral semaglutide (Rybelsus) in people seeking treatment for AUD. Novo Nordisk itself, meanwhile, recently started a phase 2 ...

Amid rising demand and Eli Lilly's Mounjaro launch, Novo Nordisk is advancing plans to introduce its obesity drug Wegovy in ...

Many online pharmacies offer Rybelsus, provided you have a valid prescription from a licensed healthcare professional, such as a primary care physician, endocrinologist, or nurse practitioner.